MNPR – monopar therapeutics inc. (US:NASDAQ)
Stock Stats
News
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Form SCHEDULE 13G/A Monopar Therapeutics Filed by: ASTRAZENECA PLC
Form SCHEDULE 13D/A Monopar Therapeutics Filed by: Tactic Pharma LLC
Form 4 Monopar Therapeutics For: Jan 28 Filed by: Robinson Chandler
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Robinson Chandler
Form 4 Monopar Therapeutics For: Dec 31 Filed by: Cittadine Andrew
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.